Innovative solutions to
keep your project on course

Study Design and Conduct

Collection of relevant and high-quality Phase 1 clinical pharmacology study data requires both robust protocol design and experienced study oversight. Careful planning with the help of a clinical pharmacologist or pharmacokineticist is crucial to avoid missteps in your clinical studies.

Nuventra has extensive experience with the design, conduct, analysis, and interpretation of data from each type of Phase 1 clinical pharmacology study needed for an individual drug development program.

While we can conduct any Phase 1 study, our focus and expertise in clinical pharmacology is our differentiator. This is about much more than just conducting one study, it’s about an integrated approach to designing, conducting, analyzing, and interpreting Phase 1 studies within the context of your overall drug development program. As part of the study design phase, our senior consultants will conduct a review of your clinical pharmacology strategy to establish an understanding of existing data and how to maximize the impact of the next study on the overall plan.

Clinical Pharmacology Studies Supported

Phase 1 Study Design and Conduct Services

  • Clinical pharmacology strategy development/review
  • Study design and protocol development
  • Study startup activities
  • Data management (eCRF, randomization, database build, edit check, etc.)
  • Robust PK analysis and standalone PK Report
  • Biostatistics
  • Clinical study report (CSR)
  • Study management
  • Clinical monitoring
  • Medical monitoring
  • CDISC datasets
  • Documents that are eCTD-publishing ready
  • Post-study update, if necessary, to clinical pharmacology strategy

Explore Our Blog

Federal and Regulatory Support for the Development of Novel Antibiotics

Antibiotics are among the most important medications in the modern healthcare toolbox and are essential safeguards against global pandemics. However,…

Read More
Intrinsic and Extrinsic Factors

Intrinsic and Extrinsic Factors in Drug Development

Personalized medicine (also known as precision medicine) is one of today’s biggest drug development buzzwords. It certainly stirs the imagination…

Read More

FDA Policies to Accelerate Development of Cell & Gene Therapies

FDA Commissioner Scott Gottlieb, M.D. and Director of the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D.,…

Read More